Atomoxetine Accord 40 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

atomoxetine accord 40 mg kapseli, kova

accord healthcare b.v. - atomoxetine hydrochloride - kapseli, kova - 40 mg - atomoksetiini

Atomoxetine Accord 60 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

atomoxetine accord 60 mg kapseli, kova

accord healthcare b.v. - atomoxetine hydrochloride - kapseli, kova - 60 mg - atomoksetiini

Atomoxetine Accord 80 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

atomoxetine accord 80 mg kapseli, kova

accord healthcare b.v. - atomoxetine hydrochloride - kapseli, kova - 80 mg - atomoksetiini

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

FLUVASTATIN RATIOPHARM 80 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

fluvastatin ratiopharm 80 mg depottabletti

ratiopharm gmbh - fluvastatinum natricum - depottabletti - 80 mg - fluvastatiini

DORZOLAMID/TIMOLOL ACTAVIS 20 mg/ml + 5 mg/ml silmätipat, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

dorzolamid/timolol actavis 20 mg/ml + 5 mg/ml silmätipat, liuos

actavis group ptc ehf - dorzolamidi hydrochloridum,timololi maleas - silmätipat, liuos - 20 mg/ml + 5 mg/ml - timololi, yhdistelmävalmisteet

Ropinirol Orion 2 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ropinirol orion 2 mg depottabletti

orion corporation - ropinirole hydrochloride - depottabletti - 2 mg - ropiniroli

Ropinirol Orion 4 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ropinirol orion 4 mg depottabletti

orion corporation - ropinirole hydrochloride - depottabletti - 4 mg - ropiniroli

Ropinirol Orion 8 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ropinirol orion 8 mg depottabletti

orion corporation - ropinirole hydrochloride - depottabletti - 8 mg - ropiniroli

Ropinostad 2 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ropinostad 2 mg depottabletti

stada arzneimittel ag - ropinirole hydrochloride - depottabletti - 2 mg - ropiniroli